Scientific Publications by FDA Staff
Clin Vaccine Immunol 2012 May;19(5):731-9
Analysis of Defined Combinations of Monoclonal Antibodies in Anthrax Toxin Neutralization Assays and Their Synergistic Action.
Ngundi MM, Meade BD, Little SF, Quinn CP, Corbett CR, Brady RA, Burns DL
Antibodies against the protective antigen (PA) component of anthrax toxin play an important role in protection against disease caused by Bacillus anthracis. In this study, we examined defined combinations of PA-specific monoclonal antibodies for their ability to neutralize anthrax toxin in cell culture assays. We observed additive, synergistic and antagonistic effects of the antibodies depending on the specific antibody combination examined and the specific assay used. Synergistic toxin neutralizing antibody interactions were examined in more detail. We found that one mechanism that can lead to antibody synergy is the bridging of PA monomers by one antibody with resultant bivalent binding of the second antibody. These results may aid in optimal design of new vaccines and antibody therapies against anthrax.
|Category: Journal Article|
|PubMed ID: #22441391||DOI: 10.1128/CVI.05714-11|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2011-12-02||Entry Last Modified: 2012-09-09|